Cover Image

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Thanawin Pramotedham, Yong Chuan Tan
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
by: Mary Yue Wang, et al.
Published: (2026)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
by: Lucie Simonis, et al.
Published: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
by: Eduardo Vilar‐Gomez, et al.
Published: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
by: Stephanie Tsai, et al.
Published: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
by: Shuai Xia, et al.
Published: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
by: Bingqiong Wang, et al.
Published: (2025)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
by: Lucie Simonis, et al.
Published: (2025)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
by: Supachaya Sriphoosanaphan, et al.
Published: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
by: Luis Calzadilla Bertot, et al.
Published: (2025)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation
by: David Tornai, et al.
Published: (2025)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
by: David Tornai, et al.
Published: (2026)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
by: Nina Kimer, et al.
Published: (2024)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
by: Adriana Palom, et al.
Published: (2026)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
by: Mo‐Yao Tan, et al.
Published: (2024)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
by: Emily Stephenson, et al.
Published: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
by: Jimmy Che‐To Lai, et al.
Published: (2026)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
by: Mary Yue Wang, et al.
Published: (2025)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
by: Abdulrahman Ismaiel
Published: (2026)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
by: Huiying Lin, et al.
Published: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
by: Louise J. M. Alferink, et al.
Published: (2024)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
by: Glenn Jun Kit Ho, et al.
Published: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
by: Bernardo de Faria Moraes, et al.
Published: (2026)

Editorial: Decoding Gut Failure in Cirrhosis—Villin‐1 and the Emergence of a Seventh Organ Failure. Authors' Reply
by: David Tornai, et al.
Published: (2026)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
by: Ting Wang, et al.
Published: (2024)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
by: William Chai, et al.
Published: (2025)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
by: Deliang Huang, et al.
Published: (2026)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
by: Yuki Utakata, et al.
Published: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
by: Zhanbo Qu
Published: (2026)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
by: Yu Shi, et al.
Published: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
by: Sai Kiran Kuchana, et al.
Published: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
by: Yuki Utakata, et al.
Published: (2026)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
by: Mei Chin Lim, et al.
Published: (2026)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
by: Yee Hui Yeo, et al.
Published: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
by: Andrew W. Nguyen, et al.
Published: (2026)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Soroor Owrangi, et al.
Published: (2024)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
by: Christian Labenz, et al.
Published: (2026)

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions
by: Julian Pohl, et al.
Published: (2025)

Editorial: Quantity is important!
by: Chee‐Kiat Tan
Published: (2024)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
by: Bernardo de Faria Moraes, et al.
Published: (2026)

Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort
by: Scott Silvey, et al.
Published: (2025)